News
Long Island experts weigh in after Novo Nordisk ends deal with Hims & Hers over weight loss meds
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss since late April in order to transition patients off compounded drugs, or off-label versions of the medication, according to the news release.
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...
Asianet Newsable on MSN11h
Hims & Hers CEO Says 'No Way In Hell We're Gonna Cave On' Selling Compounded Obesity Drugs After Novo Nordisk BreakupTruist warned that Hims faces renewed litigation risk after Novo's exit, which could create a prolonged legal overhang on the ...
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has increasingly prioritized weight loss as a key ...
Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock ...
Tesla shares rise sharply after the electric-vehicle company launched its highly anticipated robo-taxi service in Austin, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback